Theragen and GenVec combine stables

One of the many dangers facing start-up companies is that the failure of one technology will leave the company with no fall-back position or that their technology base will prove to be too narrow to support a successful business. The search for a technology platform was the driving force behind the merger last week of two privately held gene therapy companies, Theragen Inc. and GenVec Inc.